First patients to receive experimental liver cancer drug
NCT ID NCT06478693
Summary
This is the first study in humans testing a new drug called MT-303 for advanced liver cancer that has spread or cannot be removed by surgery. Researchers will give the drug alone or combined with standard cancer medications to 70 participants to find the safest dose and see if it helps control the cancer. The main goal is to understand how the body handles the drug and what side effects it causes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cha University Bundang Medical Center
RECRUITINGGyeonggi-do, South Korea
Contact
-
Integrated Clinical Oncology Network (ICON) Pty Ltd
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact
-
Linear Clinical Research
RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact
-
Pusan National Univesity Hospital
RECRUITINGBusan, South Korea
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
-
St Vincent's Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
Contact
-
Taipei Tzu Chi Hospital
RECRUITINGTaipei, Taiwan
Contact
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact
Conditions
Explore the condition pages connected to this study.